Pharma's developing interest in stem cells.
Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corporate strategies.
McKernan
Ruth
R
Pfizer Regenerative Medicine, Cambridge, UK. ruth.mckernan@pfizer.com
McNeish
John
J
Smith
Devyn
D
D064987:Cell- and Tissue-Based Therapy / Q000191:economics; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care; D055808:Drug Discovery; D004345:Drug Industry / Q000191:economics; D006801:Humans; D013234:Stem Cells